1. Home
  2. INDP vs OXBR Comparison

INDP vs OXBR Comparison

Compare INDP & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • OXBR
  • Stock Information
  • Founded
  • INDP 2000
  • OXBR 2013
  • Country
  • INDP United States
  • OXBR Cayman Islands
  • Employees
  • INDP N/A
  • OXBR N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • OXBR Property-Casualty Insurers
  • Sector
  • INDP Health Care
  • OXBR Finance
  • Exchange
  • INDP Nasdaq
  • OXBR Nasdaq
  • Market Cap
  • INDP 15.4M
  • OXBR 15.8M
  • IPO Year
  • INDP N/A
  • OXBR 2014
  • Fundamental
  • Price
  • INDP $1.13
  • OXBR $2.51
  • Analyst Decision
  • INDP Strong Buy
  • OXBR
  • Analyst Count
  • INDP 1
  • OXBR 0
  • Target Price
  • INDP $12.00
  • OXBR N/A
  • AVG Volume (30 Days)
  • INDP 20.6K
  • OXBR 15.6K
  • Earning Date
  • INDP 11-04-2024
  • OXBR 11-12-2024
  • Dividend Yield
  • INDP N/A
  • OXBR N/A
  • EPS Growth
  • INDP N/A
  • OXBR N/A
  • EPS
  • INDP N/A
  • OXBR N/A
  • Revenue
  • INDP N/A
  • OXBR N/A
  • Revenue This Year
  • INDP N/A
  • OXBR N/A
  • Revenue Next Year
  • INDP N/A
  • OXBR N/A
  • P/E Ratio
  • INDP N/A
  • OXBR N/A
  • Revenue Growth
  • INDP N/A
  • OXBR N/A
  • 52 Week Low
  • INDP $1.03
  • OXBR $0.87
  • 52 Week High
  • INDP $3.25
  • OXBR $3.72
  • Technical
  • Relative Strength Index (RSI)
  • INDP 34.05
  • OXBR 48.72
  • Support Level
  • INDP $1.10
  • OXBR $2.32
  • Resistance Level
  • INDP $1.22
  • OXBR $2.89
  • Average True Range (ATR)
  • INDP 0.12
  • OXBR 0.20
  • MACD
  • INDP 0.00
  • OXBR -0.04
  • Stochastic Oscillator
  • INDP 16.20
  • OXBR 27.98

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts primarily for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The Company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

Share on Social Networks: